Neurocrine Biosciences, Inc. (NBIX): Price and Financial Metrics

Neurocrine Biosciences, Inc. (NBIX): $124.59

-2.22 (-1.75%)

POWR Rating

Component Grades














  • NBIX scores best on the Growth dimension, with a Growth rank ahead of 96.46% of US stocks.
  • The strongest trend for NBIX is in Growth, which has been heading up over the past 178 days.
  • NBIX's current lowest rank is in the Momentum metric (where it is better than 25.09% of US stocks).

NBIX Stock Summary

  • NBIX's current price/earnings ratio is 208.64, which is higher than 97.82% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for NBIX is currently 60.53, higher than 92.8% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of -39.19%, NEUROCRINE BIOSCIENCES INC's debt growth rate surpasses just 7.9% of about US stocks.
  • Stocks that are quantitatively similar to NBIX, based on their financial statements, market capitalization, and price volatility, are UEC, FSLR, BMRN, AGYS, and NABL.
  • Visit NBIX's SEC page to see the company's official filings. To visit the company's web site, go to

NBIX Valuation Summary

  • NBIX's price/sales ratio is 8.8; this is 76% higher than that of the median Healthcare stock.
  • NBIX's price/sales ratio has moved down 41.8 over the prior 243 months.

Below are key valuation metrics over time for NBIX.

Stock Date P/S P/B P/E EV/EBIT
NBIX 2022-12-02 8.8 7.9 209.5 129.2
NBIX 2022-12-01 8.7 7.9 208.6 128.7
NBIX 2022-11-30 8.8 7.9 209.9 129.4
NBIX 2022-11-29 8.4 7.6 201.1 124.0
NBIX 2022-11-28 8.4 7.6 201.0 123.9
NBIX 2022-11-25 8.5 7.6 201.8 124.4

NBIX Growth Metrics

    The 4 year price growth rate now stands at 149.17%.
  • Its year over year price growth rate is now at -3.49%.
  • The 2 year net cashflow from operations growth rate now stands at -57.49%.
NBIX's revenue has moved up $1,065,418,000 over the prior 52 months.

The table below shows NBIX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1,388.7 200.6 58.2
2022-06-30 1,296.8 163.6 12.2
2022-03-31 1,207.5 128.7 71.4
2021-12-31 1,133.5 256.5 89.6
2021-09-30 1,069.4 341.2 444.8
2021-06-30 1,031.9 261.9 364.7

NBIX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NBIX has a Quality Grade of B, ranking ahead of 78.08% of graded US stocks.
  • NBIX's asset turnover comes in at 0.566 -- ranking 66th of 682 Pharmaceutical Products stocks.
  • LGND, MNKD, and MRK are the stocks whose asset turnover ratios are most correlated with NBIX.

The table below shows NBIX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.566 0.988 0.102
2021-06-30 0.586 0.989 0.063
2021-03-31 0.634 0.990 0.092
2020-12-31 0.684 0.990 0.105
2020-09-30 0.733 0.991 0.118
2020-06-30 0.750 0.991 0.199

NBIX Price Target

For more insight on analysts targets of NBIX, see our NBIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $122.19 Average Broker Recommendation 1.52 (Moderate Buy)

NBIX Stock Price Chart Interactive Chart >

Price chart for NBIX

NBIX Price/Volume Stats

Current price $124.59 52-week high $129.29
Prev. close $126.81 52-week low $71.88
Day low $123.02 Volume 99,553
Day high $126.30 Avg. volume 790,564
50-day MA $114.88 Dividend yield N/A
200-day MA $100.39 Market Cap 11.98B

Neurocrine Biosciences, Inc. (NBIX) Company Bio

Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company was founded in 1992 and is based in San Diego, California.

NBIX Latest News Stream

Event/Time News Detail
Loading, please wait...

NBIX Latest Social Stream

Loading social stream, please wait...

View Full NBIX Social Stream

Latest NBIX News From Around the Web

Below are the latest news stories about NEUROCRINE BIOSCIENCES INC that investors may wish to consider to help them evaluate NBIX as an investment opportunity.

Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases

Hot biotech stock leaders are surging within the IBD 50 elite list, with some passing buy points and others building bases. Catalyst now holds the top spot in the IBD 50 and leads an industry group of more than 800 companies. This biotech stock was Monday's IBD Stock Of The Day. It is also an IBD Tech Leader member and an IBD 50 Growth Stock to Watch.

Yahoo | November 25, 2022

Dow Jones Futures Rise: 5 Stocks Near Buy Points In Market Rally; Tesla FSD Beta Expands Widely

The S&P 500 still faces its 200-day line with key economic data looming. Tesla FSD Beta gets a wide release after TSLA stock jumped from bear market lows.

Yahoo | November 25, 2022

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:

Yahoo | November 8, 2022

3 Reasons Growth Investors Will Love Neurocrine (NBIX)

Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.

Yahoo | November 4, 2022

Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows

Ironwood (IRWD) beat earnings estimates in the third quarter. Sales, though missing estimates, rose year over year. Stock up.

Yahoo | November 4, 2022

Read More 'NBIX' Stories Here

NBIX Price Returns

1-mo 2.27%
3-mo 20.94%
6-mo 27.31%
1-year 56.36%
3-year 6.66%
5-year 78.47%
YTD 46.28%
2021 -11.14%
2020 -10.83%
2019 50.53%
2018 -7.96%
2017 100.49%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8736 seconds.